Nektar Therapeutics reported 1.1M in Interest Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Baxter International BAX:US 4M 1000K
BioCryst Pharmaceuticals BCRX:US 609K 555K
Biogen BIIB:US 12.6M 9.7M
Bluebird Bio BLUE:US 174K 68K
Cara Therapeutics CARA:US 266K 104K
Eli Lilly LLY:US 10.2M 3.2M
Esperion Therapeutics ESPR:US 400K 100K
Exelixis EXEL:US 4.76M 2.94M
Ironwood Pharmaceuticals IRWD:US 1.02M 788K
Karyopharm Therapeutics KPTI:US 293K 219K
Nektar Therapeutics NKTR:US 1.1M 701K
Pfizer PFE:US 30M 16M
Sarepta Therapeutics SRPT:US 2.41M 2.24M
Xencor XNCR:US 717K 64K